|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: QKI |
Gene summary for QKI |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | QKI | Gene ID | 9444 |
| Gene name | QKI, KH domain containing RNA binding | |
| Gene Alias | Hqk | |
| Cytomap | 6q26 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96PU8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9444 | QKI | CA_HPV_1 | Human | Cervix | CC | 1.17e-05 | 1.66e-01 | 0.0264 |
| 9444 | QKI | CCI_1 | Human | Cervix | CC | 6.11e-04 | 6.94e-01 | 0.528 |
| 9444 | QKI | CCI_2 | Human | Cervix | CC | 2.92e-09 | 1.10e+00 | 0.5249 |
| 9444 | QKI | CCI_3 | Human | Cervix | CC | 2.25e-03 | 6.76e-01 | 0.516 |
| 9444 | QKI | AEH-subject1 | Human | Endometrium | AEH | 2.35e-29 | 6.44e-01 | -0.3059 |
| 9444 | QKI | AEH-subject2 | Human | Endometrium | AEH | 2.01e-11 | 3.83e-01 | -0.2525 |
| 9444 | QKI | AEH-subject3 | Human | Endometrium | AEH | 1.72e-13 | 4.15e-01 | -0.2576 |
| 9444 | QKI | AEH-subject4 | Human | Endometrium | AEH | 1.69e-31 | 7.80e-01 | -0.2657 |
| 9444 | QKI | AEH-subject5 | Human | Endometrium | AEH | 1.06e-28 | 7.60e-01 | -0.2953 |
| 9444 | QKI | EEC-subject1 | Human | Endometrium | EEC | 1.08e-24 | 6.42e-01 | -0.2682 |
| 9444 | QKI | EEC-subject2 | Human | Endometrium | EEC | 8.15e-05 | 2.55e-01 | -0.2607 |
| 9444 | QKI | EEC-subject3 | Human | Endometrium | EEC | 2.77e-16 | 2.13e-01 | -0.2525 |
| 9444 | QKI | EEC-subject4 | Human | Endometrium | EEC | 2.88e-04 | 2.40e-01 | -0.2571 |
| 9444 | QKI | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.51e-21 | 1.10e-01 | -0.1869 |
| 9444 | QKI | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.21e-16 | 4.35e-02 | -0.1875 |
| 9444 | QKI | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.14e-22 | 1.92e-02 | -0.1883 |
| 9444 | QKI | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.77e-16 | 3.58e-01 | -0.1934 |
| 9444 | QKI | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.35e-24 | 2.71e-02 | -0.1917 |
| 9444 | QKI | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 8.92e-21 | -5.32e-02 | -0.1916 |
| 9444 | QKI | LZE4T | Human | Esophagus | ESCC | 5.64e-06 | -9.85e-02 | 0.0811 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
| GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:004802410 | Cervix | CC | regulation of mRNA splicing, via spliceosome | 28/2311 | 101/18723 | 2.41e-05 | 4.19e-04 | 28 |
| GO:00512368 | Cervix | CC | establishment of RNA localization | 39/2311 | 166/18723 | 4.76e-05 | 7.25e-04 | 39 |
| GO:00506578 | Cervix | CC | nucleic acid transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
| GO:00506588 | Cervix | CC | RNA transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
| GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
| GO:00015704 | Cervix | CC | vasculogenesis | 22/2311 | 80/18723 | 1.97e-04 | 2.26e-03 | 22 |
| GO:000640310 | Cervix | CC | RNA localization | 43/2311 | 201/18723 | 2.00e-04 | 2.29e-03 | 43 |
| GO:00510284 | Cervix | CC | mRNA transport | 31/2311 | 130/18723 | 2.05e-04 | 2.33e-03 | 31 |
| GO:00426924 | Cervix | CC | muscle cell differentiation | 69/2311 | 384/18723 | 8.12e-04 | 7.09e-03 | 69 |
| GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
| GO:00159318 | Cervix | CC | nucleobase-containing compound transport | 43/2311 | 222/18723 | 1.72e-03 | 1.30e-02 | 43 |
| GO:000037710 | Cervix | CC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
| GO:000039810 | Cervix | CC | mRNA splicing, via spliceosome | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
| GO:000037510 | Cervix | CC | RNA splicing, via transesterification reactions | 55/2311 | 324/18723 | 8.61e-03 | 4.44e-02 | 55 |
| GO:000838016 | Endometrium | AEH | RNA splicing | 111/2100 | 434/18723 | 2.42e-17 | 1.12e-14 | 111 |
| GO:004348416 | Endometrium | AEH | regulation of RNA splicing | 55/2100 | 148/18723 | 1.28e-16 | 5.49e-14 | 55 |
| GO:000037515 | Endometrium | AEH | RNA splicing, via transesterification reactions | 88/2100 | 324/18723 | 1.11e-15 | 3.91e-13 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| QKI | SNV | Missense_Mutation | c.766N>G | p.Arg256Gly | p.R256G | Q96PU8 | protein_coding | tolerated(0.4) | benign(0.351) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| QKI | SNV | Missense_Mutation | rs777858938 | c.956N>A | p.Arg319Gln | p.R319Q | Q96PU8 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
| QKI | SNV | Missense_Mutation | c.169N>C | p.Tyr57His | p.Y57H | Q96PU8 | protein_coding | deleterious(0) | possibly_damaging(0.827) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| QKI | SNV | Missense_Mutation | c.938C>T | p.Ala313Val | p.A313V | Q96PU8 | protein_coding | deleterious(0.01) | benign(0.119) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| QKI | SNV | Missense_Mutation | novel | c.640N>T | p.Leu214Phe | p.L214F | Q96PU8 | protein_coding | tolerated(0.36) | benign(0.24) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| QKI | SNV | Missense_Mutation | c.889N>A | p.Ala297Thr | p.A297T | Q96PU8 | protein_coding | tolerated(0.16) | possibly_damaging(0.78) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| QKI | SNV | Missense_Mutation | rs777858938 | c.956N>A | p.Arg319Gln | p.R319Q | Q96PU8 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| QKI | SNV | Missense_Mutation | rs779943694 | c.989G>A | p.Arg330Lys | p.R330K | Q96PU8 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.991) | TCGA-F4-6809-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| QKI | SNV | Missense_Mutation | rs142647102 | c.725N>A | p.Arg242His | p.R242H | Q96PU8 | protein_coding | tolerated(0.06) | possibly_damaging(0.769) | TCGA-EI-7002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | irinotecan+5-fluorouracilim | SD |
| QKI | SNV | Missense_Mutation | c.1000N>A | p.Ala334Thr | p.A334T | Q96PU8 | protein_coding | tolerated_low_confidence(0.49) | probably_damaging(0.972) | TCGA-EI-7002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | irinotecan+5-fluorouracilim | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |